Sensitivity
97.3 %
- EndpointCase-level ICH detection
- Population376 US NCCTs, 188 positive and 188 negative
- Tested versionJLK-ICH in K243363
FDA-cleared profile
JLK, Inc. · CT/CTA · FDA-cleared (510(k))
Authorized purpose: Notification-only triage of suspected intracranial hemorrhage on non-contrast head CT
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Notification-only triage of suspected intracranial hemorrhage on non-contrast head CT
Evidence takeaway. Evidence from the reviewed source record: Standalone retrospective study of 376 US NCCTs (188 ICH-positive, 188 negative) with two ABR-certified neuroradiologists and third-reader consensus. Test data were newly acquired and independent of development data.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Packet wording: "JLK-ICH is a notification-only, parallel workflow tool that is intended to assist hospital networks and trained clinicians to identify and communicate images of specific patients to specialists, independent of the standard of care workflow." … "Specifically, the device analyzes non-contrast CT images of the head to detect intracranial hemorrhage (ICH).". Read from the exact FDA decision document on 2026-11-14.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Case-level ICH detection in the 376-scan standalone study; not a subtype-specific claim.
97.3 %
97.9 %
K243363
PMID:40116947 · doi:10.1007/s00234-025-03560-x
Publication identifies company-employed authors. It is family contextual evidence, not an independent replication or a substitute for FDA study results.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Price not public here; enter your quote
Not verified: Pricing information is recorded but not verified against a resolving source.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: DICOM non-contrast head CT from DICOM-compliant devices
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-05 · JLK-ICH: K243363 decision and 510(k) summary
Source context, not route validation: DICOM-compatible image transfer and processing; notifications are delivered through the JLK mobile application.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-05 · JLK-ICH: K243363 decision and 510(k) summary
Source context, not route validation: The exact FDA package describes JLK-ICH as an image analysis algorithm hosted on JLK servers, which receive head CT scans forwarded from CT scanners, and a mobile application for notification management. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "JLK-ICH comprises an image analysis algorithm hosted on JLK servers and a mobile application for notification management." … "The AI/ML-based algorithm is designed to analyze NCCT of the head scans forwarded from CT scanners to the JLK servers.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 · JLK-ICH: K243363 decision and 510(k) summary
Source context, not route validation: Case-level suspected-ICH notification and non-diagnostic compressed image preview in a mobile app; no marking, highlighting or segmentation on the original image.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-05 · JLK-ICH: K243363 decision and 510(k) summary
Unresolved route: Case-level suspected-ICH notification and non-diagnostic compressed image preview in a mobile app; no marking, highlighting or segmentation on the original image.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-05 · JLK-ICH: K243363 decision and 510(k) summary
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Packet wording: "JLK-ICH comprises an image analysis algorithm hosted on JLK servers and a mobile application for notification management." … "The AI/ML-based algorithm is designed to analyze NCCT of the head scans forwarded from CT scanners to the JLK servers.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Vendor statement, not an attestation; exact-release scope is not established.
Vendor describes JLK-ICH as part of its MEDIHUB stroke portfolio.
product family · checked 2026-09-05Current portfolio claims for other modalities and modules are not capabilities of K243363.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The cleared input is NCCT; the catalog's CT/CTA controlled category does not imply CTA use.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
Stored PubMed candidate and publication metadata/full-text record reviewed; it names JLK-ICH but has company-employed authors and unestablished exact version, so retained only as non-independent product-family context. Stored trial array is empty. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor product page, literature index, peer reviewed publication, trial registry, recall database, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No primary-source US commercial price reviewed.
Bounded web search on 2026-10-26 (query: "JLK ICH SDH reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Mobile-app notification response training and local escalation protocol remain unestablished.
Local notification latency, false-alert and missed-alert monitoring commitments require confirmation.
10 sources - 3 history items
Scope: identity, clinical, evidence, implementation, deployment
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: identity, clinical, evidence, implementation
Scope: implementation
Scope: evidenceStudies
Scope: security
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Methinks Software S.L.
Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.
iSchemaView
Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.
Methinks Software S.L.
Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.
SK Inc.
Authorized purpose: Notification-only triage for suspected acute intracranial hemorrhage on non-contrast brain CT, sharing cases with medical specialists in parallel with standard care.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history